 |
|
Reviparin in Acute Myocardial Infarction
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation (CREATE)1 concludes that, in patients with acute ST-elevation myocardial infarction (STEMI), reviparin reduces overall mortality and reinfarction at 7 days (P = .005) and 30 days (P = .001). This is a megatrial involving 15 570 patients designed to detect a 15% relative risk (RR) reduction on the composite outcome at 7 days with a power of 93%. Although this conclusion is correct based on the applied analysis, it is important to examine the magnitude of the composite mortality reduction. The CREATE trial is similar to the Facile Interpretation of Statistical Hypotheses (FISH) trial postulated by Diamond and Kaul.2 The CREATE trial shows an absolute reduction in the first coprimary composite outcome at 7 days of 1.4%. Using a Bayesian approach with a noninformative prior (prior log odds ratio [OR] distribution with mean, 0 . . . [Full Text of this Article]
Francesco Buccelletti, MD
francesco.buccelletti@mssm.edu
Mount Sinai School of Medicine
New York, NY
RELATED ARTICLES
Reviparin in Acute Myocardial Infarction
Andrew T. Yan, Raymond T. Yan, and Shaun G. Goodman
JAMA. 2005;293(21):2595.
EXTRACT
| FULL TEXT
Reviparin in Acute Myocardial Infarction—Reply
Salim Yusuf, Chanchun Xie, and Janice Pogue
JAMA. 2005;293(21):2595-2596.
EXTRACT
| FULL TEXT
Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
The CREATE Trial Group Investigators*
JAMA. 2005;293(4):427-435.
ABSTRACT
| FULL TEXT
|
